The Talisker Whisky Atlantic Challenge is one of the toughest challenges anyone has ever undertaken for Leukaemia & Lymphoma Research.
So it's fair to say that we are honoured to have been chosen by Atlantic Row 2013 as one of their charities and are utterly inspired by the determination the guys have shown throughout.
Dan and Will have very personal reasons for supporting Leukaemia & Lymphoma Research, as Will’s father was diagnosed with non-Hodgkin lymphoma in 2006 and is now in remission. Around 17,000 adults, children and teenagers are diagnosed with lymphoma in the UK every year. Thanks to our research, lymphoma is now much more successfully treated than ever before. The ultimate goal of our research is to develop truly personalised treatments for lymphoma to ensure that all patients are given the best possible chance of survival.
There are more than 35 different types of lymphoma, which respond to different treatments. Diagnosing different types of lymphomas relies on identifying specific marker molecules on the surface of the blood cancer cells. Current research continues to improve diagnosis for rare forms of lymphoma by characterising these marker molecules more precisely. Improved diagnosis has driven the development of better treatments.
Pioneering new treatments
Our researchers in Edinburgh are investigating how the body’s own immune system could be enhanced to attack lymphoma cells. This research has shown that lymphoma tumours are able to hijack a patient’s natural defence system in order to grow, by sending out chemical messages to specific immune cells in the blood. Our scientists are exploring ways of blocking these signals so they can develop new drugs to treat patients with lymphoma more effectively.
Reducing side effects
Treatment for lymphoma is still fairly aggressive, often involving radiotherapy, which can have damaging long-term side effects. Our research is pioneering new treatments that are safer and more effective.
Research in Cambridge is exploring the role that specific genes play in causing various forms of lymphoma. This will help to develop more targeted treatments that have fewer side effects and allow patients to enjoy a better quality of life after treatment.
“Our world-class research includes the whole spectrum of disciplines from basic laboratory research, which is vital for understanding how blood cancers develop, pioneering new treatments and improving diagnosis; translational research, which brings a detailed understanding of the diseases to develop and refine treatments and clinical trials, that test new treatments in patients and ultimately save more lives.”
Professor Chris Bunce, Research Director
Dan and Will’s efforts, which have already raised an incredible amount, will help us to continue investing in new life-saving research and give more patients the chance to live a full and healthy life after treatment. We’re following their progress closely and couldn’t be more proud of them.
Please support them and help beat blood cancer by donating now
Post provided by Bekah Morris, Leukaemia & Lymphoma Research